<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2015">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134935</url>
  </required_header>
  <id_info>
    <org_study_id>NISDO</org_study_id>
    <nct_id>NCT05134935</nct_id>
  </id_info>
  <brief_title>Defocus (DIMS) Spectacles Versus Ortho-K Lenses (OKL) for Slowing Myopia Progression in Danish Children Aged 6-12 Years.</brief_title>
  <acronym>NISDO</acronym>
  <official_title>Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS) Versus Orthokerathology Lenses (OKL) for Slowing Myopia Progression in Danish Children Aged 6-12 Years. The Noninferiority NISDO Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare the myopia control efficacy of Ortho-K lenses (OKL) and Defocus&#xD;
      (DIMS) spectacles in Danish myopic children aged 6-12 years. It is a clinical randomized&#xD;
      non-inferiority trial, where the participants are randomly assigned to either OKL or DIMS&#xD;
      spectacles. The participants are followed during 18 months of therapy. The hypotheses:&#xD;
&#xD;
        -  There is no statistically significant difference between the myopia control efficacy&#xD;
           between OKL and DIMS spectacles.&#xD;
&#xD;
        -  Larger pupil size is positively correlated to treatment efficacy for both devises.&#xD;
&#xD;
        -  Increasing choroidal thickness during early treatment is positively correlated to&#xD;
           treatment efficacy for both devises.&#xD;
&#xD;
        -  There is no difference in vision related quality of life between the two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2022</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Axial length growth of the eye</measure>
    <time_frame>During 18 months of therapy</time_frame>
    <description>Length is measured in mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall eye length growth, defined as the sum of axial length and choroidal thickness</measure>
    <time_frame>During 18 months of therapy</time_frame>
    <description>Length is measured in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupil size</measure>
    <time_frame>During 6 months of therapy</time_frame>
    <description>Length is measured in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Choroidal thickness</measure>
    <time_frame>During 18 months of therapy</time_frame>
    <description>Thickness is measured in um</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision related quality of life using the questionnaire PREP2</measure>
    <time_frame>Prior to and 9 months after treatment initiation</time_frame>
    <description>Range from &quot;strongly disagree&quot; to &quot;strongly agree&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>OKL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DIMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defocus Incorporated Multiple Segment (DIMS) Spectacles</intervention_name>
    <description>18 months of therapy.</description>
    <arm_group_label>DIMS</arm_group_label>
    <other_name>Defocus (DIMS) Spectacles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orthokerathology lenses (OKL)</intervention_name>
    <description>18 months of therapy.</description>
    <arm_group_label>OKL</arm_group_label>
    <other_name>Night lenses</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Myopic children aged 6 to 12 years. Myopia of the 6 to 8-year-olds: -1.00 to -4.75 D&#xD;
             spherical component and up to -2.50 D of regular astigmatism. Myopia of the 9 to&#xD;
             12-year-olds: -2.00 to -4.75 D spherical component and up to -2.50 D of regular&#xD;
             astigmatism.&#xD;
&#xD;
          -  Anisometropia &lt; 1,5 D cycloplegic spherical equivalent refractive error.&#xD;
&#xD;
          -  Best corrected visual acuity: Age 6 to 8 (inclusive) years: 0.8 Snellen (equivalent to&#xD;
             ≥ 3/5 letter on the 0.8 line = 78 ETDRS letters). Age 9 to 12 years: 1.0 Snellen&#xD;
             (equivalent to ≥ 3/5 letter on the 1.0 line = 83 ETDRS letters)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Manifest or latent squint.&#xD;
&#xD;
          -  Contraindications to the use of OKL comprising keratoconus, chronic allergic&#xD;
             conjunctivitis and keratoconjunctivitis sicca.&#xD;
&#xD;
          -  Previous eye surgery.&#xD;
&#xD;
          -  Chronic eye disease demanding daily use of eye drops.&#xD;
&#xD;
          -  Non-compliance to eye examinations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lou-Ann Andersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lou-Ann Andersen</last_name>
    <phone>+45 79 40 64 50</phone>
    <email>Lou-Ann.C.Andersen@rsyd.dk</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

